Yourgene Health PLC
LSE:YGEN
Intrinsic Value
Yourgene Health Plc engages in the development and commercialization of genomic services and technologies. [ Read More ]
The intrinsic value of one
YGEN
stock under the Base Case scenario is
3.326
GBX.
Compared to the current market price of 0.515 GBX,
Yourgene Health PLC
is
Undervalued by 85%.
Yourgene Health PLC's market capitalization is 16.4m GBX.
YGEN stock price is 0.515 GBX.
YGEN stock price (0.515 GBX) is 85% less than its Intrinsic Value (3.326 GBX).
YGEN. Open DCF Valuation
YGEN stock price (0.515 GBX) is 85% less than its Relative Value (3.326 GBX). Open Relative Valuation
YGEN has upside potential of 114% compared to the average analyst price target.
Open Wall St Estimates
YGEN's Revenue has grown by 8% over the past 12 months.
YGEN's ROIC (Return on Invested Capital) has increased in the last 3 years from -19% to -12%, and is approaching profitability.
YGEN's short-term assets (13m GBP) exceed its short-term liabilties (9m GBP).
YGEN's ROE (Return on Equity) has significantly increased in the last 3 years from -41% to -27%, and is approaching profitability.
YGEN's long-term assets (55m GBP) exceed its long-term liabilties (29m GBP).
YGEN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -12%.
YGEN's Revenue is forecast to fall at a rate of 17% per year over the next 3 years.
YGEN's D/E (Debt to Equity) is very low and is equal to 0.58.
YGEN has negative Operating Income for the last twelve months.
YGEN has negative Net Income for the last twelve months.
YGEN's ROE (Return on Equity) for the past 12 months is negative and is equal to -27%.
YGEN has positive Gross Profit for the last twelve months.
YGEN's Altman Z-Score is very low and is equal to 1.49.
YGEN has negative three-year average ROE (Return on Equity): -10%. The company is not efficient at transforming stockholders' equity into net income.
YGEN has positive Net Debt. This means that the company has more debt (15m GBP) than cash and short-term investments (2m GBP).
YGEN has negative three-year average ROIC (Return on Invested Capital): -11%. The company is not efficient at using invested capital to generate operating income.
YGEN has negative Free Cash Flow for the last twelve months.
YGEN doesn't generate enough operating income (-6m GBP) to safely cover interest payments on its debt (718k GBP).
Valuation Backtest
Yourgene Health PLC
Run backtest to discover the historical profit from buying and selling
YGEN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Yourgene Health PLC
Balance Sheet Decomposition
Yourgene Health PLC
| Current Assets | 13m |
| Cash & Short-Term Investments | 2.4m |
| Receivables | 5.4m |
| Other Current Assets | 5.2m |
| Non-Current Assets | 41.8m |
| PP&E | 18.1m |
| Intangibles | 21.8m |
| Other Non-Current Assets | 1.9m |
| Current Liabilities | 9.5m |
| Accounts Payable | 5.7m |
| Other Current Liabilities | 3.8m |
| Non-Current Liabilities | 19.3m |
| Long-Term Debt | 15m |
| Other Non-Current Liabilities | 4.3m |
Earnings Waterfall
Yourgene Health PLC
|
Revenue
|
29.7m
GBP
|
|
Cost of Revenue
|
-13.2m
GBP
|
|
Gross Profit
|
16.5m
GBP
|
|
Operating Expenses
|
-22.2m
GBP
|
|
Operating Income
|
-5.7m
GBP
|
|
Other Expenses
|
-2.4m
GBP
|
|
Net Income
|
-8.2m
GBP
|
Free Cash Flow Analysis
Yourgene Health PLC
YGEN Profitability Score
Profitability Due Diligence
Yourgene Health PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Yourgene Health PLC's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
YGEN Solvency Score
Solvency Due Diligence
Yourgene Health PLC's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Yourgene Health PLC's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
YGEN Price Targets Summary
Yourgene Health PLC
According to Wall Street analysts, the average 1-year price target for
YGEN
is 1.1 GBX
.
Shareholder Return
YGEN Price
Yourgene Health PLC
| Average Annual Return | 2.25% |
| Standard Deviation of Annual Returns | 16.07% |
| Max Drawdown | -99% |
| Market Capitalization | 16.4m GBX |
| Shares Outstanding | 3 193 469 952 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Yourgene Health PLC
Country
Industry
Market Cap
Dividend Yield
Description
Yourgene Health Plc engages in the development and commercialization of genomic services and technologies. The principal activity of the Company is that of a molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for prenatal screening and other clinical applications in the early detection, monitoring and treatment of disease. The firm operates through two segments. The Genomic Technologies segment provides the in vitro diagnostic products, software and instrumentation manufactured by the Company and distributed globally through its direct and indirect sales channels. The Genomic Services segment operates testing laboratories in Taiwan and the United Kingdom and provides services to clinicians, third party clinical service providers and contract research organizations. These services require similar technical, commercial and managerial competences in the two host countries, and sometimes consume the output from the Genomic Technologies segment.
Contact
IPO
Employees
Officers
The intrinsic value of one
YGEN
stock under the Base Case scenario is
3.326
GBX.
Compared to the current market price of 0.515 GBX,
Yourgene Health PLC
is
Undervalued by 85%.
You don't have any saved screeners yet
